SCHEMBL25534765

SCHEMBL25534765

c1ccc(-c2nc(-c3cccc4ccccc34)cc(-c3ccc(-c4cccc(-c5ccc6c(c5)C(c5ccccc5)(c5ccccc5)c5ccccc5-6)c4)c4ccccc34)n2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.39
ALDH1A1 P00352 3/20 0.39
HPGD P15428 3/20 0.39
KDM4E B2RXH2 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TP53 P04637 1/20 0.39
TSHR P16473 1/20 0.39
NFKB1 P19838 1/20 0.39
MAPK1 P28482 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
ATM Q13315 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MEN1 O00255 5/20 0.36
KMT2A Q03164 5/20 0.36
MCL1 Q07820 1/20 0.36
ACMSD Q8TDX5 1/20 0.36
CA12 O43570 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25534792 0.99 ALDH1A1 (0.38) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25534619 0.98 MAPT (0.40) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25534809 0.97 MEN1 (0.37) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25538122 0.97 MEN1 (0.38) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25534627 0.96 MAPT (0.39) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25534935 0.95 ALDH1A1 (0.37) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25535090 0.95 MAPT (0.37) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25534789 0.95 CHRNA1 (0.36) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25534722 0.95 CA12 (0.41) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25534819 0.95 ALDH1A1 (0.40) MAPTALDH1A1HPGDKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167072-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO.,LTD. (JP) 2023-06-01 US disclosed
US-20230167072-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO.,LTD. (JP) 2023-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167072-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE PIEZO1, LEF1, L1CAM MAPT 1595/4885ALDH1A1 254/4885HPGD 3854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.